Moleculin Appoints Lead Principal Investigator for Upcoming Trial

Moleculin Biotech (NASDAQ:MBRX) appointed Dr. Lidia Gil of Poznan University of Medical Sciences to be the lead European Principal Investigator for its upcoming Phase I/II clinical trial of Annamycin treating relapsed or refractory acute myeloid leukemia.
As quoted in the press release:

The Company announced on June 15, 2017 that it was expanding its engagement with its CRO, Theradex Systems, Inc., to include clinical sites in Poland in order to increase access to AML patients.
“Dr. Gil is a highly-respected hematologist-oncologist in Poland,” commented Walter Klemp, Chairman and CEO of Moleculin, “and we are honored to have her leading the European element of our upcoming clinical trial for Annamycin, which would commence only if our IND is permitted.”
Dr. Robert Shepard, Moleculin’s Chief Medical Officer, added: “Dr. Gill is a dedicated investigator in AML and will bring significant expertise in the area as well as her potential to accelerate enrollment and the completion of our trial.”

Click here to read the full press release.

Source: www.marketwired.com